Literature DB >> 12210815

Acute rhabdomyolysis as a complication of cytarabine chemotherapy for acute myeloid leukemia: case report and review of literature.

Cristina I Truica1, Stanley R Frankel.   

Abstract

Rhabdomyolysis is an unusual complication of chemotherapy that can lead to substantial morbidity through such complications as renal failure, infections, and disseminated intravascular coagulation. The syndrome has been described after treatment with cyclophosphamide, 5-azacytidine, interleukin-2, and interferon and after bone marrow transplantation. We report a patient with acute myeloid leukemia who developed fulminant rhabdomyolysis after treatment with a cytarabine-containing regimen. The syndrome was complicated by acute renal failure requiring hemodyalisis, respiratory insufficiency, and pancreatitis. We suggest that the muscle damage might be related to the known ability of cytarabine to trigger the release of cytochrome c from the mitochondria, which could lead to uncoupling of the oxidative phosphorylation with subsequent depletion of ATP reserves at the skeletal muscle and rhabdomyolysis. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12210815     DOI: 10.1002/ajh.10152

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  8 in total

1.  A substrate pharmacophore for the human organic cation/carnitine transporter identifies compounds associated with rhabdomyolysis.

Authors:  Sean Ekins; Lei Diao; James E Polli
Journal:  Mol Pharm       Date:  2012-02-28       Impact factor: 4.939

2.  Tumor Lysis Syndrome and AKI: Beyond Crystal Mechanisms.

Authors:  Marine Arnaud; Maud Loiselle; Camille Vaganay; Stéphanie Pons; Emmanuel Letavernier; Jordane Demonchy; Sofiane Fodil; Manal Nouacer; Sandrine Placier; Perrine Frère; Eden Arrii; Julien Lion; Nuala Mooney; Raphael Itzykson; Chakib Djediat; Alexandre Puissant; Lara Zafrani
Journal:  J Am Soc Nephrol       Date:  2022-05-06       Impact factor: 14.978

3.  Nelarabine-induced rhabdomyolysis in a patient with T-cell acute lymphoblastic leukemia: a case report.

Authors:  Akari Utsumi; Yuri Goto; Takaaki Suzuki; Chiaki Imai; Shinichiro Matsui; Emiko Sakaida; Itsuko Ishii
Journal:  J Pharm Health Care Sci       Date:  2022-06-11

Review 4.  Chemotherapy-Related Neurotoxicity.

Authors:  Sophie Taillibert; Emilie Le Rhun; Marc C Chamberlain
Journal:  Curr Neurol Neurosci Rep       Date:  2016-09       Impact factor: 5.081

5.  Severe acute rhabdomyolysis induced by multi-agent chemotherapy for alveolar rhabdomyosarcoma in a 15-year-old female: a case report.

Authors:  Hiroshi Matsuzaki; Yuhki Koga; Aiko Suminoe; Utako Oba; Tomohito Takimoto; Toshiro Hara
Journal:  Case Rep Oncol       Date:  2013-07-31

6.  Delayed rhabdomyolysis with paclitaxel, ifosfamide, carboplatin, and etoposide regimen: a case report.

Authors:  Alexandra Sokolova; Onyee Chan; Waqas Ullah; Auon Abbas Hamdani; Faiz Anwer
Journal:  J Med Case Rep       Date:  2017-04-11

7.  Rhabdomyolysis during myelosuppression in a patient with central nervous system leukemia: A case report.

Authors:  Ying Le; Huiqun Li; Chengyao Wan; Yuan Long; Zhenfang Liu
Journal:  Medicine (Baltimore)       Date:  2018-11       Impact factor: 1.889

8.  Anti-NXP2-antibody-positive immune-mediated necrotizing myopathy associated with acute myeloid leukemia: A case report.

Authors:  Lina Su; Yue Yang; Yuan Jia; Xu Liu; Wei Zhang; Yun Yuan; Zhanguo Li
Journal:  Medicine (Baltimore)       Date:  2018-07       Impact factor: 1.889

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.